Business Wire

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2021 results. “The tremendous progress we made ...

Ironwood to cut 100 jobs after acid reflux drug fails study

Ironwood Pharmaceuticals Inc said on Tuesday it will cut about 100 jobs after its therapy to treat digestive disorder refractory gastroesophageal reflux failed to significantly reduce heartburn ...
Business Wire

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS ® Prescription Demand

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its second quarter 2022 results and recent business performance. “We made ...